Looking to the Horizon: Emerging Therapies and the Near Future Evolution in Prostate Cancer

Looking to the Horizon: Emerging Therapies and the Near Future Evolution in Prostate Cancer

Wednesday, February 15, 2023
Webinar -- 7:00 PM PT
https://www.clinicaloptions.com/GUProstateSS2023Join1

Agenda

  • Welcome and Introductions
  • PSMA Targeting
  • PARP Inhibitors: How Do They Fit Into the Treatment Landscape?
  • Emerging Investigational Targets and Novel Immunotherapy Approaches
  • Panel Discussion: Unanswered Questions
  • Audience Question and Answer Throughout the Symposium

Faculty

Program Director
Neeraj Agarwal, MD, FASCO

Professor of Medicine
Senior Director for Clinical Research Innovation, Huntsman Cancer Institute (HCI)
Presidential Endowed Chair of Cancer Research
Director, Center of Investigational Therapeutics
Director, Genitourinary Oncology Program
Huntsman Cancer Institute, University of Utah (NCI-CCC)

Faculty
Tanya B. Dorff, MD

Clinical Associate Professor
Department of Medical Oncology & Therapeutics Research
City of Hope
Duarte, California

Faculty
Rana McKay, MD

Associate Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
University of California, San Diego
Genitourinary Oncology Team Lead
Moores Cancer Center
La Jolla, California

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in the integration of novel therapies into the care of patients with prostate cancer.

Target Audience
This educational program is intended for medical oncologists, urologists, and other healthcare professionals who treat patients with prostate cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Appraise novel therapeutically actionable molecular targets that hold promise as predictive or prognostic biomarkers for patients with prostate cancer
  • Plan optimal, individualized sequential therapeutic strategies for prostate cancer, considering all available agents, clinical data including novel investigational therapeutics and imaging techniques, and expert recommendations
  • Identify patients with prostate cancer who may be eligible for enrollment on ongoing clinical studies investigating novel regimens
  • Assess recent trial evidence from studies that evaluated novel approaches for prostate cancer in the context of their impact on evolving paradigms in the field

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.